TetraLogic: Oppenheimer Healthcare Conference (TetraLogic) - Dec 28, 2014 - “Results: Four subjects (~27%) demonstrated PRs by 50% reduction in CAILS score from baseline at Days 28 or 42, Subjects on placebo demonstrated no significant improvements, No significant safety events observed: no SAEs, no discontinuations, no DLTs, no systemic sequelae (AEs: mild skin burning, erythema)“
P1 data • Oncology
|